Edition:
United Kingdom

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.67USD
19 Jan 2018
Change (% chg)

$0.04 (+2.45%)
Prev Close
$1.63
Open
$1.62
Day's High
$1.68
Day's Low
$1.61
Volume
2,182
Avg. Vol
15,756
52-wk High
$2.85
52-wk Low
$1.03

Chart for

About

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's... (more)

Overall

Beta: 2.31
Market Cap(Mil.): $92.11
Shares Outstanding(Mil.): 56.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Vermillion Announces Agreement With Bluecross Blueshield Of Illinois

* VERMILLION ANNOUNCES AGREEMENT WITH BLUECROSS BLUESHIELD OF ILLINOIS Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Vermillion Appoints Bob Beechey To Newly Created CFO Post

* VERMILLION - MOST RECENTLY, BEECHEY WAS VICE PRESIDENT AND GENERAL MANAGER OF Q SQUARED SOLUTIONS BIOANALYTICAL, ADME LABORATORY OPERATIONS Source text for Eikon: Further company coverage:

19 Dec 2017

BRIEF-Vermillion reports third quarter loss of $0.06 per share

* Qtrly net loss per share attributable to common stockholders basic and diluted $0.06‍​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

08 Nov 2017

BRIEF-‍Aspira Labs says has entered into agreements to provide coverage for OVA1​

* ‍Aspira Labs says has entered into agreements to provide coverage for its in vitro diagnostic test, OVA1​

27 Oct 2017

BRIEF-Vermillion to report Q3 results on Nov 8

* Vermillion to report third quarter 2017 financial results and host investor conference call on November 8th Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Vermillion files for mixed shelf of up to $50 mln - SEC filing

* Vermillion files for mixed shelf of up to $50 million - SEC filing Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Aspira Labs announces in-network contract agreement with Healthnet Federal Services for OVA1

* Aspira Labs announces in-network contract agreement with Healthnet Federal Services for OVA1

02 Oct 2017

BRIEF-Vermillion reports Q2 loss per share $0.04

* Q2 revenue rose 27 percent to $898,000 Source text for Eikon: Further company coverage:

09 Aug 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $59.31 +0.24
Becton Dickinson and Co (BDX.N) $234.51 +2.39
Arrayit Corp (ARYC.PK) $0.01 -0.00

Earnings vs. Estimates